Autoimmune Encephalitis
54
16
20
17
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
1.9%
1 terminated out of 54 trials
94.4%
+7.9% vs benchmark
4%
2 trials in Phase 3/4
6%
1 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 17 completed trials
Clinical Trials (54)
Biomarkers in Autoimmune Disease of Nervous System
Relapse and Functional Outcomes in Anti-LGI1 Encephalitis
Cohort Study on Neuroimmune Diseases in the Reproductive Age
IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2
A Study in Participants With Anti-NMDAR Encephalitis and Anti-NMDAR Autoantibody-Associated Psychiatric Disease
Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants
Phase 1 Study of ART5803 in Healthy Participants
FDG-PET in the Diagnosis of Autoimmune Encephalitis
Study of Pathogenic Mechanisms and Identification of Novel Autoantibodies in Autoimmune Encephalitis
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
Tongji NADs Cohort
A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy
Long-term Impact of NMDAR Encephalitis
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases
Monitoring of Outcomes of Cellular and Exosome-based Therapies in Autoinflammatory and Post-infectious Neuroinflammatory Syndromes
Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis
A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis
Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism
hUC-MSC-Exo Therapy for Autoimmune Encephalitis
Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis